Drug profile · INN
silver sulfadiazine
SILVADENE
silver sulfadiazine (SILVADENE) is a bacterial dihydropteroate synthase inhibitor. Route of administration: topical. Current US regulatory status: approved.
Drug details — silver sulfadiazine
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
silver sulfadiazine (SILVADENE) is a bacterial dihydropteroate synthase inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial dihydropteroate synthase inhibitor
Primary target: Dihydropteroate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is silver sulfadiazine?
silver sulfadiazine (SILVADENE) is a bacterial dihydropteroate synthase inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for silver sulfadiazine?
SILVADENE is a marketed brand name for silver sulfadiazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of silver sulfadiazine?
silver sulfadiazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.